Neuralink clinical trials evaluate whether the N1 implant can help people with severe paralysis control computers and other devices using neural signals.
Exact criteria depend on the specific study and site. Current research has focused on adults with severe paralysis such as quadriplegia related to spinal cord injury or ALS who meet medical screening requirements, including protocol age/stability rules, visit ability, caregiver considerations where required, and exclusions for conflicting implants or conditions.
Neuralink's trials page now also lists brain stem stroke for its device-control trials, and the VOICE speech trial enrolls people with ALS, PLS, stroke, or spinal cord injury who have severe speech impairment, according to its trial record.
Only Neuralink screening can confirm a match.
Neuralink may cover study-related costs such as travel. That support covers participation expenses and is not a salary. Joining the patient registry is not a paid job.
See also How Much Does Neuralink Cost?.
Neuralink reported 21 participants ("Neuralnauts") on January 28, 2026. Neura Pod's patient table counted 27+ publicly identified patients as of June 2026. The implant is not sold to the public; access is through Neuralink's clinical trials and patient registry.
No salary. Study-related costs such as travel may be covered.
No. It is a screening pathway for trials.